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Summary
Context Familial glucocorticoid deficiency (FGD) is a rare auto-
somal recessive disorder as a result of mutation in genes encoding
either the ACTH receptor [melanocortin 2 receptor (MC2R)] or its
accessory protein [melanocortin 2 receptor accessory protein
(MRAP)]. The disorder is known as FGD type 1 and 2, respectively.
Objective The aim of the study was to compare the phenotype/
genotype relationships between FGD 1 and 2.
Design and patients Forty patients with missense MC2R muta-
tions and 22 patients with MRAP mutations were included. Forty-
four of these patients had been referred for genetic screening and
18 were patients published by other authors.
Results The median age at presentation for FGD type 1 was vari-
able at 2Æ0 years; range 0Æ02–16 years, and this was associated with
unusually tall stature, mean height SDS + 1Æ75 ± 1Æ53 (mean ±
SD). In contrast, FGD type 2 presented at a much earlier median
age (0Æ08 years; range at birth to 1Æ6 years) (P < 0Æ01) and patients
were of normal height SDS + 0Æ12 ± 1Æ35 (P < 0Æ001). No differ-
ences in baseline cortisol or ACTH levels were seen between FGD
types 1 and 2.
Conclusion FGD type 2 appears to present earlier. This may
reflect the functional significance of the underlying mutations in
that all MRAP mutations are nonsense or splice site mutations that
result in abolition of a functional protein, whereas most of the
MC2R mutations are missense mutations and give rise to proteins
with some residual function. Tall stature is associated with muta-
tions in MC2R but not in MRAP. There were no other significant
clinical distinctions between the two.
(Received 27 April 2009; returned for revision 19 May 2009; finally
revised 25 May 2009; accepted 27 May 2009)
Introduction
Familial glucocorticoid deficiency (FGD) or hereditary unrespon-
siveness to ACTH is characterized by isolated glucocorticoid
deficiency. It is an autosomal recessive disorder resulting from
ACTH resistance, typically presenting between the neonatal period
and late childhood; with hyperpigmentation, hypoglycaemia and
seizure.1–4 The first inactivating melanocortin 2 receptor (MC2R)
mutations in FGD were described in 1993.5,6 Since then, multiple
mutations have been identified throughout the receptor, the
majority of which are homozygous or compound heterozygous
missense mutations; FGD resulting from MC2R mutations
accounts for 25% of all FGD and is now known as FGD type 1
(OMIM#202200). FGD type 2 (OMIM*609196) describes a group
of patients with normal MC2R but with mutation in the melano-
cortin 2 receptor accessory protein (MRAP) which is required for
MC2R trafficking and function7 and this accounts for 20% of
FGD and is now known as FGD type 2.8
There are at least 25 missense mutations of MC2R identified in
FGD type 1. In vitro functional studies have shown that the major-
ity of MC2R mutations do not function because they fail to traffic
to the cell surface.9 Nine mutations of MRAP in FGD type 2
have been reported to date, all of which are splice site or nonsense
mutations and are predicted to produce proteins lacking the trans-
membrane domain essential for interaction with MC2R.7,9–11
This paper compares the phenotypes of all previously reported
(and some unreported) FGD type 1 and 2 patients and their bio-
chemical findings. As MRAP is expressed more widely than
MC2R,7 and because of evidence that it may interact with other
melanocortin receptors,12 we have considered whether the FGD
type 2 phenotype may differ from that of FGD type 1, perhaps
reflecting a broader spectrum of activity than that of the MC2R. Of
particular relevance is the report that a patient with FGD type 2
was significantly obese from childhood, which prompted the
authors to speculate that MRAP may have a role in the appetite
regulatory function of MC4R in the hypothalamus.11
Patients andmethods
Patients
One hundred and sixty-four patients were referred to us from 1993
to 2008 for genetic screening with a clinical diagnosis of FGD
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characterized by elevated plasma ACTH, and low or undetectable
cortisol in the absence of overt mineralocorticoid deficiency. Other
causes of adrenal insufficiency were excluded. From this cohort, 26
patients with FGD type 1 and 18 with FGD type 2 were identified.
All clinical details and information given by the referring physician
were included in the analysis.
We also performed a PubMed search for all genetically
identified FGD type 1 and 2 cases reported until December 2008
and this resulted in a further 18 patients being included in this
study.
Mutational analysis of MC2R andMRAP
Genomic DNA was extracted from peripheral leucocytes from the
index patients. Polymerase chain reaction (PCR) amplification was
performed using specific intronic primers designed to MRAP and
MC2R genes (primer sequences and PCR conditions available on
request). All mutations were confirmed with a second PCR and
parental DNA where possible. PCR products were sequenced using
an ABI 3700 genetic analyser, according to the manufacturer’s
protocol (Applied Biosystems, Foster City, CA, USA).
Statistical evaluation
Data were tested for normality on spss software Version 16 (SPSS
Inc., Chicago, IL, USA). For normally distributed data, the two
groups were compared using independent t-test. Values are stated
as the mean ± sd, unless otherwise stated. Significance was defined
as P < 0Æ05.
Results
We included in the analysis 40 FGD type 1 patients with 21 differ-
ent MC2R mutations in homozygous or compound heterozygous
form and 22 FGD type 2 patients with 9 different MRAP mutations
(Fig. 1). The majority of the MC2Rmutations have been previously
reported,13–25 and of these the S74I mutation was present in 18
patients. All nine mutations have previously been reported for
FGD type 2.7,11,26,27
Data included in the comparisons were the age of presentation,
height (in SDS), weight (in SDS) of subjects at presentation, bio-
chemical parameters including ACTH and cortisol levels and
response to short synacthen testing (where available). Insufficient
data were available to comment on bone age, final adult height or
adrenal androgen production.
Age at presentation
FGD type 1 presents with a variable age of onset, median age is
2Æ0 years (range 0–16 years; mean age 3Æ11 ± 3Æ40 years), while
FGD type 2 presents at an earlier age withmedian onset at 0Æ08 years
(range 0–1Æ6 years; mean age 0Æ31 ± 0Æ51 years), P < 0Æ01 (Fig. 2a).
The most common MC2R mutation, homozygosity for S74I,
appears to display a wide spectrum in age of presentation, with the
median age of onset 3Æ2 years (range 0–16) which does not differ
from that of other patients with FGD type 1 (Fig. 2a).
Height andweight at presentation
The height of patients with FGD type 1 has previously been noted
to be unusually tall.2,16,28 In FGD type 1, height SDS at presentation
was +1Æ76 ± 1Æ52 (mean ± SD) and in FGD type 2 height SDS at
presentation was +0Æ12 ± 1Æ35, P < 0Æ001 (Fig. 2b). Not all weight
measurements were available for FGD 1. Where data were present,
the mean weight SDS for FGD type 1 (n = 19) at presentation was
+1Æ7 ± 1Æ46 and in FGD type 2 (n = 14), the mean weight SDS at
presentation was +0Æ718 ± 1Æ62 (NS) (Fig. 3).
ACTH/cortisol at presentation
The median plasma ACTH (range) at presentation for FGD
type 1 was 1409 (250–6888) ng/l and 1250 (108–4500) ng/l for
FGD type 2 (NS) (Fig. 4a). Similarly, the basal cortisol at
presentation is shown in Fig. 4b, with FGD type 1 median cortisol
50 (8–502) nmol/l and FGD type 2 median cortisol 50
(5Æ5–200) nmol/l (NS).
Discussion
The diagnosis of FGD is based on clinical findings and patients
usually present with hypoglycaemia, seizure, jaundice, hyperpig-
mentation, failure to thrive and frequent or severe infections. The
biochemical findings are a markedly elevated plasma ACTH in the
presence of low cortisol but with a preserved mineralocorticoid
production and are characteristic of ACTH insensitivity. There are
two genetically identified causes of FGD – mutations in the MC2R
and mutations in MRAP known as FGD type 1 and 2, respectively.
This is the first phenotype–genotype comparison between FGD
types 1 and 2.
We have shown in in vitro studies that missense mutations in the
MC2R have varying degrees of impaired trafficking from the endo-
plasmic reticulum (ER) to the cell surface resulting in reduced
receptor expression (20–100% when compared with wild-type)
and ACTH signalling.9 Consequently, there is often some protein
with residual function. In contrast, MRAP is required in the earliest
stages of MC2R processing and in the absence of MRAP protein,
the receptor is retained within the ER.7,9,29 G protein-coupled
receptors which are trapped in the ER are subject to degradation by
retrotranslocation and proteasomal degradation.30 All MRAP
mutations reported so far will prevent translation of the full-length
protein. There is evidence that MRAPmay also play a role in ACTH
binding and/or signalling,31 and without MRAP, the MC2 receptor
will not traffic efficiently to the cell surface leading to complete fail-
ure of receptor function. Studies of the expression of the MRAP
gene in humans reveal a wider pattern of expression than that of
the MC2R.7 This suggests that MRAP may have additional roles to
those related to the MC2R, and we have demonstrated an inter-
action with each of the melanocortin receptors.12 Therefore, exam-
ination of any discrepancies between FGD types 1 and 2 may
provide important clues to other functions of MRAP. It has been
proposed that MRAP may also facilitate expression or function of
the MC4R and that this could account for the marked obesity
observed in a child with FGD type 2.11
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When the clinical features of FGD types 1 and 2 were compared,
striking distinctions were discovered in the age of presentation and
height, but not in other aspects of endocrinology or body weight.
The correlation between the estimated severity of the receptor
defect in vitro and the degree of clinical severity remains poor. This
was evident even for patients with the same MC2R mutation such
as the most commonly occurring, S74I substitution in which the
phenotype ranged from minimal to severe. Plotting height vs. age
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Fig. 1 Pseudostructural plot of MC2R (a) and MRAP (b) showing the positions of the mutations included in this analysis. Copyright permission obtained
from Elsevier publishing group.36
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appears to be suggestive of a relationship between length of expo-
sure to high ACTH/low glucocorticoid and tall stature, but we
could not detect statistical significance.
Unusually tall stature has been described in many FGD type
1 cases in the literature,1,3,4,28 the cause of which is not
known. In vitro, ACTH increases the development of a chon-
drogenic phenotype with an increase in proliferation and
differentiation of chondrocyte precursors.32 Consequently, it is a
reasonable hypothesis that ACTH at high concentrations could
activate melanocortin receptors expressed in bone and the car-
tilaginous growth plate and stimulate growth.33 In adrenalec-
tomized leptin-deficient mice given c2-MSH, it was found that
there were positive changes in linear growth parameters (both
naso-anal and tibial length), suggesting that the melanocortin
system plays a role in linear growth.33 Alternatively, glucocor-
ticoid inhibits the synthesis of IGF binding protein 5 (IGFBP-
5) in the osteoblast.34 Bone growth is stimulated by IGFBP-5,
and thus conceivably cortisol deficiency results in a lack of
negative inhibition and the consequent growth spurt seen in
FGD type 1. No abnormality in the GH–IGF–I axis has been
reported in FGD patients to date. It is interesting to note that
MC2R knockout mice do not exhibit any significant difference
in body length when compared with wild-type.35
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Fig. 2 Age and height of FGD patients at presentation. (a) Age (years) of all
patients with FGD type 1, those patients with the S74I mutation, and FGD
type 2 are shown. The horizontal line represents the mean. (b) Height (in
SDS) of all patients with FGD type 1 and FGD type 2 are shown. The
horizontal line represents the mean. **P < 0Æ01; ***P < 0Æ001.
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Fig. 4 Plasma ACTH and cortisol at presentation. (a) ACTH (ng/l) and (b)
cortisol (nmol/l) for all patients with FGD type 1 and 2 are shown. The
horizontal line represents the mean. No statistical significance was detected
in the two groups.
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Fig. 3 Weight of FGD patients at presentation. The weight (in SDS) of all
patients with FGD type 1 and 2 are shown. The horizontal line presents the
mean. There was no statistical significance detected.
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Clinical observations suggest that replacement of glucocorticoid
normalizes the advanced growth rate in FGD.16,28 In the reported
cases, despite adequate hydrocortisone replacement, ACTH often
remains elevated. The discordance of the plasma ACTH and bone
growth suggest that exposure to cortisol could play a role in
this. However, it is also very difficult to exclude the possibility that
overtreatment with glucocorticoids is responsible for this decelera-
tion in growth.
In conclusion, patients with familial glucocorticoid deficiency
type 1 present later and have tall stature when compared with
familial glucocorticoid deficiency type 2. This is consistent with the
suggestion that prolonged ACTH excess or glucocorticoid defi-
ciency increases linear growth. Familial glucocorticoid deficiency
type 2, in contrast, presents earlier and appropriate treatment may
be sufficient to prevent the enhanced growth rate seen in familial
glucocorticoid deficiency type 1. There was no evidence that mela-
nocortin 2 receptor accessory protein deficiency had any influence
on any other physiological function beyond that seen with a defec-
tive melanocortin 2 receptor.
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